The 3D bioprinting sector has failed to deliver on its expectations of providing solutions within the regenerative medicine industry. The reason that the bioprinting field is failing is due to technological limitations. Their shortcomings are either based on lack of processing speed, their inability to keep the cells intact and functional, as well as their limitation of creating the diversity that is needed to create a realistic human tissue. Beyond a realistic functionality of these tissues they also lack additional functionality (conditions or processes within the tissue itself).

The organisation
The first start-up to merge advanced electric, magnetic, & microfluidic biofabrication technology with novel cyborganic technology to create high throughput tissues & organs with embedded bioelectronics, biosensors, and therapeutic agents. The team brings business and industry experts together with academic experts. Together they have 50+ years of combined experience in research and corporate environment.

Business activities
The company focuses on the 4D biofabrication of realistic human tissues embedded with biosensors, bioelectronics and/or therapeutic agents. They can be used by researchers and developers to create a better understanding of diseases, for the development of new treatments, safety testing and improvement of existing treatments. It will increase development speed and time to market for important healthcare solutions. For scalability and more standardization in development, the proprietary advanced bioprinting platform that is currently under development will be used. Focus on:

• Manufacturing ready Prototype, 0-series,
• Sensor embedded In-vitro model: Manufacturing ready Prototype

The market
The regenerative medicine industry is a fast-growing market with a CAGR of over 25% and is estimated to reach $116B in 2026. Currently animal models are still widely used for this purpose. There has been clear statement from both US and EU on making 2035 the target year to disband all animal trials. At the moment there are limited solutions available to replace or reduce $16B animal trials market.

Particularities
The new platform will allow the printing of multiple biomaterials in any composition in gradient to create diversity in the 3D tissue. It will utilize advanced tissue engineering technologies as 3D Bioelectrospraying, Cell Electrospinning, and Electrohydrodynamic Jet Bioprinting. These “electric field” technologies are recognized in many publications for their superiority in keeping cells alive and functional which is essential to make realistic tissue. The company will be marketing both products as well as services. Pricing of the cyborganic application will be market driven and depending on the complexity of the offered or required cyborganic application. The Human biomaterials will be a support product line. The initial cyborganics applications will involve the 4D In-Vitro tissue models, but in the long-term vision also include potential therapeutic applications. The services that will be promoted and sold are the development of tailored sensor embedded tissue models.

Other information
The largest group of stakeholders within the Regenerative medicine market are hospitals. Besides the academic hospitals being involved in research related to regenerative medicine solutions they are also the biggest user of any new clinical applications in this field. There are approximately 8.000 research centers in the world with each having different specialized departments or research groups. Due to the extraordinary costs of advanced systems, only a few have access to advance technology as far that is now available. Although exact numbers are not known what is known is that since the discovery of 3D cell culturing the number of research publications on this subject has increased exponentially. Other stakeholders involved more in tissue engineering and/or the utilization of the advanced in-vitro models are contract research organizations.

Possibilities
The company is working towards 2 potential exit strategies besides using the company as a cash cow. One of the strategies would be to go public and the other would focus on the company being acquired.